Dengue on the rise worldwide: economic burden, silent spread – and renewed hope with Brazil’s new vaccine

Dengue, once mostly confined to tropical regions, has expanded its reach. In recent years, countries across Latin America, Asia, and Africa – and even some regions previously considered low risk – have reported growing numbers of infections, reflecting climate change, urban sprawl, and increasing global travel. The social and economic costs of this spread are heavy, but the recent announcement of a new dengue vaccine from Brazil’s Instituto Butantan offers renewed hope for long-term control.

Dengue imposes a substantial global burden on health systems and economies. A landmark global analysis estimated that, in 2013, there were roughly 58.4 million symptomatic dengue infections worldwide, generating an estimated US$ 8.9 billion per year in direct and indirect costs. More recent projections evaluate that between 2020 and 2050 dengue could cost the global economy around US$ 306 billion, factoring in healthcare costs, lost workdays, productivity losses and long-term social impacts.

In many of the hardest-hit nations – especially those with limited sanitation, weak vector-control programs, and under-resourced health systems – dengue exacerbates inequality, strains public services, and destabilizes livelihoods. Recurring outbreaks overload hospitals, heighten fatality risks, and deepen socio-economic vulnerabilities.

Amid that urgency, the Butantan Institute’s vaccine project stands out. In 2025, data from its large-scale clinical trial – which enrolled 16,000 volunteers – showed 89% protection against severe dengue and dengue with warning signs. The plan is to produce the vaccine at scale, with a target of up to 60 million doses per year for Brazil’s vaccination campaigns.

The vaccine isn’t a silver bullet – dengue has four distinct serotypes, and environmental conditions that favor mosquito proliferation remain. But a safe, effective immunization program can dramatically reduce hospitalizations, deaths, and relieve the financial and societal burden, especially in endemic regions or areas vulnerable to outbreaks.

The arrival of this vaccine renews the need for robust public health investment: sanitation, vector surveillance, public education and rapid response systems. It also demonstrates that in a globalized world facing climate change and disease resurgence, science remains one of the strongest tools against emerging threats – old or new.